Evidence map›Paper›PMID 34496892›Full record

ArticleJournal of nanobiotechnology2021

Extracellular vesicles derived from CD73 modified human umbilical cord mesenchymal stem cells ameliorate inflammation after spinal cord injury.

Xiao Zhai, Kai Chen, Huan Yang, Bo Li, Tianjunke Zhou, Haojue Wang, Huipeng Zhou, Shaofeng Chen, Xiaoyi Zhou, Xiaozhao Wei and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Rewiring the Spine-Cutting-Edge Stem Cell Therapies for Spinal Cord Repair.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Xiao Zhai *Department of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Kai Chen *Department of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Huan Yang *Department of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Bo Li *Department of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Tianjunke Zhou *Basic Medicine College, Naval Medical University, Shanghai, 200433, China.
Haojue Wang *Basic Medicine College, Naval Medical University, Shanghai, 200433, China.
Huipeng ZhouDepartment of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Shaofeng ChenDepartment of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Xiaoyi ZhouDepartment of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Xiaozhao WeiDepartment of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. weixianzhao@126.com.
Yushu BaiDepartment of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. spinebaiys@163.com.
Ming LiDepartment of Orthopedics, Shanghai Changhai Hospital, Naval Medical University, Shanghai, 200433, China. limingchspine@126.com.ORCID http://orcid.org/0000-0002-6245-4468
Second Military Medical University · CN

Funding

National Natural Science Foundation of China 81701199Science and Technology Commission of Shanghai Municipality 16DZ0504000Science and Technology Commission of Shanghai Municipality 17441900500State Administration of Traditional Chinese Medicine of the People's Republic of China ZY[2018-2020]-FWTX-2005
6 · The paper itself

Abstract

backgroundSpinal cord injury (SCI) is an inflammatory condition, and excessive adenosine triphosphate (ATP) is released into the extracellular space, which can be catabolized into adenosine by CD73. Extracellular vesicles have been designed as nano drug carriers in many diseases. However, their impacts on delivery of CD73 after SCI are not yet known. We aimed to construct CD73 modified extracellular vesicles and explore the anti-inflammatory effects after SCI.

methodsCD73 engineered extracellular vesicles (CD73+ hucMSC-EVs) were firstly established, which were derived from human umbilical cord mesenchymal stem cells (hucMSCs) transduced by lentiviral vectors to upregulate the expression of CD73. Effects of CD73+ hucMSC-EVs on hydrolyzing ATP into adenosine were detected. The polarization of M2/M1 was verified by immunofluorescence. Furthermore, A2aR and A

resultsCD73+ hucMSC-EVs reduced concentration of ATP and promoted the level of adenosine. In vitro experiments, CD73+ hucMSC-EVs increased macrophages/microglia M2:M1 polarization, activated adenosine 2b receptor (A2bR), and then promoted cAMP/PKA signaling pathway. In mice using model of thoracic spinal cord contusion injury, CD73+ hucMSC-EVs improved the functional recovery after SCI through decreasing the content of ATP in cerebrospinal fluid and improving the polarization from M1 to M2 phenotype. Thus, the cascaded pro-inflammatory cytokines were downregulated, such as TNF-α, IL-1β, and IL-6, while the anti-inflammatory cytokines were upregulated, such as IL-10 and IL-4.

conclusionsCD73+ hucMSC-EVs ameliorated inflammation after spinal cord injury by reducing extracellular ATP, promoting A2bR/cAMP/PKA pathway and M2/M1 polarization. CD73+ hucMSC-EVs might be promising nano drugs for clinical application in SCI therapy.

Indexed as

5'-NucleotidaseAdenosine TriphosphateAnimalsCyclic AMPCytokinesDown-RegulationExtracellular VesiclesHumansInflammationMacrophagesMaleMesenchymal Stem CellsMiceMice, Inbred ICRProto-Oncogene Proteins c-aktReceptor, Adenosine A2B5'-NucleotidaseAdenosine TriphosphateCyclic AMPCytokinesProto-Oncogene Proteins c-aktReceptor, Adenosine A2BCD73Extracellular vesiclesInflammationMesenchymal stem cellSpinal cord injury

Identifiers

PMID34496892
PMCPMC8425042
OpenAlexW3197004892

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.